Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New test piloted for childhood leukaemia

05.08.2002


A new screening test to be piloted in Bristol could help to revolutionise the way children with leukaemia are treated by enabling doctors to fine tune treatment to the needs of each individual patient.



Experts from five centres - Bristol, Glasgow, Leeds, London and Sheffield - will pilot the test for the most common form of the childhood leukaemia - acute lymphoblastic leukaemia (ALL). The team at the University of Bristol and Bristol Royal Hospital for Children is using special technology called RQ- PCR (real time quantitative polymerase chain reaction) to measure the residual cancer cells - known as minimum residual disease - that remain after a child`s treatment.

All children treated for this cancer will have some residual leukaemia cells in their bone marrow that remain after the first month of chemotherapy. The level may fluctuate between 1/20 cells and 1/ 10,000 cells. Research in the UK and Europe has shown that the higher the level of residual disease the more likely a child is to relapse. Until now, the problem has been that conventional techniques are not sensitive enough to accurately measure the levels of residual leukaemia cells.


Dr Nick Goulden from the Bristol Royal Hospital for Children, says: "Preliminary studies have demonstrated that measuring residual disease enables us to predict whether a child will relapse. We hope that once this test is established in the UK doctors will be able to intervene at an earlier stage with more or less aggressive therapy based on the level of residual disease present in the blood and bone marrow."

In total the five research teams have been awarded £500,000 from the Leukaemia Research Fund to carry out a feasibility study before the test can become a central component of the next national trial (see notes for editors).

Once the genetic fingerprint of a leukaemia cell has been identified, the residual cells can be quickly and accurately tested using the new RQ-PCR technology. This is a relatively new technique which allows scientists to amplify a given sequence of DNA millions of times within the space of a few hours.

One family who understands the importance of this research is the Baggley family from Taunton, whose daughter Olivia was diagnosed with acute lymphoblastic leukaemia in 1997 when she was five years old.

"It is only when you are faced with this disease that you realise how important research is to improving treatment," says Olivia`s mother Deborah. "I hope this research will make treatment simpler and even help to save the lives of children who may otherwise have relapsed and died."

Olivia - who is now 10 years - was treated with intensive chemotherapy at Bristol Royal Hospital for Children. When the disease returned early in January 2000 the doctors decided the best option was a stem cell transplant. She has now been in remission for two years.

Dr David Grant, Scientific Director of the Leukaemia Research Fund, said: "This is a key step forward which should lead to better treatment for every single child who is diagnosed with this terrible disease."

"It should enable doctors to give more immediate and more appropriate treatment for children with a high risk disease. Equally, it would also allow doctors to identify children who could be cured with less intensive treatment, thereby reducing the gruelling side-effects of aggressive treatment," he added.

Around 21,500 people are diagnosed with leukaemia or one of the related blood disorders in the UK every year.

Leukaemia Research Fund is the only national charity devoted exclusively to improving treatments, finding cures and learning how to prevent leukaemia, Hodgkin`s disease and other lymphomas, myeloma and the related blood disorders, diagnosed in 21,500 people in Britain every year.

Further information, including patient booklets, is available from:
· your nearest LRF voluntary fundraising Branch (see Yellow Pages)
· LRF, 43 Great Ormond Street, London, WC1N 3JJ tel 020 7269 9068; emailinfo@lrf.org.uk; www.lrf.org.uk.

Joanne Fryer | alfa

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>